Clinical Trials Browser

Phase 1 × INDUSTRY × SCLC, Extensive Stage × Clear all

NCT05116007 2024-05-31

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Phase 1 Completed

SCLC, Extensive Stage